UPDATE: On December 10, 2020, the Supreme Court of Canada dismissed Pfizer’s application for leave to appeal (Docket No. 39150) (see article here).
As previously reported, Justice O’Reilly of the Federal Court granted Pharmascience’s motion for a summary trial on Pfizer’s defence of ex turpi causa in an action for section 8 damages related to pregabalin (Pfizer’s LYRICA) under the pre-amended Patented Medicines (Notice of Compliance) Regulations. The judge held that Pfizer’s defence of ex turpi causa by reason of infringement was not legally viable as Pfizer did not bring an infringement action against Pharmascience in the real world.
On February 25, 2020, the Federal Court of Appeal dismissed Pfizer’s appeal from the Federal Court decision substantially for the reasons given by Justice O’Reilly: Pfizer Canada ULC v Pharmascience Inc., 2020 FCA 55.
The Federal Court of Appeal (FCA) rejected Pfizer’s submission that hypothetical infringement of its patent in the but-for world must be taken into account in any award of damages, noting that Pfizer not only did not bring an infringement action against Pharmascience in the real world, but also expressly confirmed on discovery that it would not have done so in the but-for world. It was the Federal Court of Appeal’s view that the majority reasons in Apotex Inc. v Sanofi-Aventis (2014 FCA 68), endorsed by the Supreme Court, are binding and dispositive of the matter. As stated by Justice O’Reilly, that decision “stands for the proposition that the absence of obstacles to market entry in the real world should prevail in the but-for world; if a generic manufacturer could have made sales without objection from the patentee, those sales should be considered in the calculation of the generic’s losses”.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
FCA finds Teva would directly infringe and induce infringement of Janssen’s paliperidone palmitate patent
As previously reported, the Federal Court found that Teva would directly infringe but not induce infringement of certain claims of Canadian Patent No. 2,655,335 (335 patent) regarding its paliperidone...Read More -
Supreme Court of Canada denies Apotex leave to appeal ONCA olanzapine Statutes of Monopolies decision
Eli Lilly had successfully obtained an order of prohibition against Apotex relating to Canadian Patent No. 2,041,113, which was later found invalid in a decision involving Novopharm (affirmed on appea...Read More -
Apotex’s section 8 claim for Apo-Atomoxetine dismissed
On March 30, 2023, the Ontario Superior Court of Justice dismissed Apotex’s claim under section 8 of the Patented Medicines (Notice of Compliance) Regulations relating to Apo-Atomoxetine (Lilly’s STRA...Read More